MX2020004218A - Métodos y composiciones para inhibir las actividades biológicas de adam10. - Google Patents

Métodos y composiciones para inhibir las actividades biológicas de adam10.

Info

Publication number
MX2020004218A
MX2020004218A MX2020004218A MX2020004218A MX2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A MX 2020004218 A MX2020004218 A MX 2020004218A
Authority
MX
Mexico
Prior art keywords
adam10
biological activities
methods
peptides
inhibiting
Prior art date
Application number
MX2020004218A
Other languages
English (en)
Inventor
Marcia L Moss
Robert Rasmussen
Chris Prince
Original Assignee
Verra Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verra Therapeutics filed Critical Verra Therapeutics
Publication of MX2020004218A publication Critical patent/MX2020004218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24081—ADAM10 endopeptidase (3.4.24.81)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se proporcionan péptidos moduladores de ADAM10 aislados modificados y métodos de uso de los mismos para modular las actividades biológicas de ADAM10, inhibir las actividades biológicas de ADAM10 asociadas a enfermedades, trastornos o afecciones en sujetos, incluyendo, pero sin limitación la reducción de la inflamación y la inhibición de la proliferación de células indeseables. En algunas realizaciones, los péptidos moduladores de ADAM10 aislados modificados se basan en la SEQ ID NO: 3 o la SEQ ID NO: 4, y en algunas realizaciones incluyen modificaciones en o cerca de los extremos N-terminal y/o C-terminal de los péptidos desvelados, así como sustituciones, inserciones y deleciones en una o más de las posiciones de los aminoácidos de los péptidos de prodominio de ADAM 10 desvelados en el presente documento.
MX2020004218A 2017-10-02 2018-10-02 Métodos y composiciones para inhibir las actividades biológicas de adam10. MX2020004218A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566580P 2017-10-02 2017-10-02
US201762589842P 2017-11-22 2017-11-22
PCT/US2018/053938 WO2019070685A1 (en) 2017-10-02 2018-10-02 METHODS AND COMPOSITIONS FOR INHIBITING BIOLOGICAL ACTIVITIES OF ADAM10

Publications (1)

Publication Number Publication Date
MX2020004218A true MX2020004218A (es) 2020-11-11

Family

ID=65995419

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004218A MX2020004218A (es) 2017-10-02 2018-10-02 Métodos y composiciones para inhibir las actividades biológicas de adam10.

Country Status (8)

Country Link
US (2) US20190345473A1 (es)
EP (1) EP3691671A4 (es)
JP (2) JP7448219B2 (es)
AU (1) AU2018345601A1 (es)
CA (1) CA3077694A1 (es)
IL (1) IL273725A (es)
MX (1) MX2020004218A (es)
WO (1) WO2019070685A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020227714A1 (en) * 2019-05-09 2020-11-12 Verra Therapeutics, Llc Methods and compositions for inhibiting adam8 biological activities
WO2023172594A2 (en) * 2022-03-08 2023-09-14 Nova Southeastern University Method for treating rheumatoid arthritis (ra) using an enzyme-and substrate selective exosite inhibitor of a disintegrin and metalloprotease 10 (adam10)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174102A (zh) * 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
US7638301B2 (en) * 2006-08-28 2009-12-29 Biozyme, Inc. Prodomain modulators of ADAM 10
WO2012064865A1 (en) 2010-11-09 2012-05-18 The University Of Chicago Role of adam10 and its relevance to disease and therapeutics
WO2012088105A2 (en) * 2010-12-20 2012-06-28 Biozyme Inc. Methods and compositions for predicting disease status in cancer

Also Published As

Publication number Publication date
EP3691671A4 (en) 2022-01-19
CA3077694A1 (en) 2019-04-11
AU2018345601A1 (en) 2020-05-21
JP7448219B2 (ja) 2024-03-12
US20190345473A1 (en) 2019-11-14
JP2024012470A (ja) 2024-01-30
WO2019070685A1 (en) 2019-04-11
IL273725A (en) 2020-05-31
JP2021500321A (ja) 2021-01-07
EP3691671A1 (en) 2020-08-12
US20230203468A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
MX2021006856A (es) Uso de un peptido para modular la homeostasis de los acidos biliares o tratamiento de una enfermedad relacionada con los acidos biliares.
UY37563A (es) Aislados de bacillus y usos de los mismos
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
MX2017004488A (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
MX2019011592A (es) Peptidos y analogos de peptidos protectores de los tejidos para evitar y tratar padecimientos y desordenes asociados con daño de los tejidos.
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
CO2018005306A2 (es) Variantes del factor viii reducido con cpg, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasia
ES2688030T3 (es) Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de enfermedades oculares inflamatorias
WO2015183890A3 (en) Methods and compositions for the treatment of metabolic disorders and diseases
UY37564A (es) Aislados de lysinibacillus y usos de los mismos
MX2013013833A (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas.
BR112018001761A2 (pt) uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética
UY33204A (es) Metodos y composiciones usando polipeptidos de fusion de fgf23
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
MX2020004218A (es) Métodos y composiciones para inhibir las actividades biológicas de adam10.
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
EA201790842A1 (ru) Белки cry1da1 с вариантами аминокислотной последовательности, обладающие активностью против чешуекрылых
NZ765759A (en) Atf5 peptide variants and uses thereof
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
NZ610620A (en) Inhibitors of apoptosis and uses thereof
MX2020011263A (es) Metodos y composiciones de agotamiento de celulas t citotoxicas.